Global Lung Cancer Therapeutics Market Size study, by Disease Type (Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)), by Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), by Sales Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecasts 2022-2028
Global Lung Cancer Therapeutics Market is valued at approximately USD 26444.84 Million in 2021 and is anticipated to grow with a healthy growth rate of more than 13 % over the forecast period 2022-2028. Lung cancer therapeutics comprise all the therapies to cure it. It is a fatal lung tumour characterised by uncontrolled cell proliferation in the lung tissues. The most significant risk factor for lung cancer is cigarette smoking. Lung cancer can also be caused by prolonged exposure to cigarette smoke. The diagnosis of lung cancer is verified by a biopsy performed under bronchoscopy or CT guidance. As a result, lung cancer can be treated using chemotherapy, radiation, immunotherapy, surgery, and other methods. Rising pollution due to Industrialization, increasing funding for Research & Development, and rising prevalence of Lung Cancer have driven the Lung Cancer Therapeutics Market. For Instance: As per the reports of the American Cancer Society, there will be 236,740 lung and bronchus cancer diagnoses and 130,180 deaths in the United States in 2022. About 85 percent of those cases are predicted to be NSCLC. Also, rising advancements in Research and development of a well-structured healthcare system are most likely to boost the overall growth of the Global Lung Cancer Therapeutics Market. However, high cost of Lung Cancer Therapeutics can obstruct the market's expansion over the projection period of 2022-2028.
The key regions considered for the global Lung Cancer Therapeutics Market study include Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading region across the world. Rising development of a well-structured healthcare system and presence of major key players is driving the market growth in North America. Whereas, Asia Pacific is also anticipated to exhibit the highest growth rate over the forecast period 20222028. The market is expected to grow during the projected period, due to rising prevalence of Lung Cancer.
Major market players included in this report are:
Genentech Inc.
Eli Lillly and Company
Celgene Corporation
AstraZeneca
Pfizer Inc.
Sanofi Pharma
Novartis AG
Merck Sharp and Dohme Corp.
Millennium Pharmaceuticals Inc.
Astellas Pharma`2
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the Therapy within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Disease Type:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC))
By Therapy:
Targeted Therapy
Immunotherapy
Chemotherapy
By Sales Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028
Target Audience of the Global Lung Cancer Therapeutics Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
Companies Mentioned
Genentech Inc.
Eli Lillly and Company
Celgene Corporation
AstraZeneca
Pfizer Inc.
Sanofi Pharma
Novartis AG
Merck Sharp and Dohme Corp.
Millennium Pharmaceuticals Inc.
Astellas Pharma`2
Please note:The single user license is non-downloadable and non-printable. Global Site license will allow these actions.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook